Guest guest Posted November 19, 2008 Report Share Posted November 19, 2008 Synagis is made by MEdimmune which makes flumist which is a terrifying vaccine with live flu viruses sprayed into noses in stores & pharmacies and is contagious for a good length of time...............Medimmune has its facilities in UK at the Chiron plant that had the contaminated flu vaccine that was blocked a few years ago........... Also some of us think that RSV may be something that follows polio vaccine - I can't explain that at the moment Or even all the other vaccines that are given at 12 houurs, 2 months, 3 months, 4 months, 6 months.............certainly lower immune system resistance. Also, never was known when I was working PEDS (didn't discover it until late 70's or something). I don't remember horror and lots of children with problems from anything resembling what they describe. Breastfeeding is excellent protection against most illness; not vaccinating is excellent protection; and finding a good homeopath if illness does come up. But in my experience (and I am in contact with thousands and thousands of non-vaccinators), non-vaccinated children are the healthiest children there are as a whole. Synagis is called a monoclonal antibody http://www.medimmune.com/products/synagis/index.asp It would be hard to tell in this age group what was a reaction to this stuff because they get so many vaccines in the same time period It is genetically engineered. If I remember right, it comes from human immunglobulin - pooled blood from a variety of people (I wouldn't want anyone's pooled blood - the risk for who knows what in my opinion is greater than any RSV illness) It doesn't say that exactly but that is the only way to get antibodies - from pooled blood immunglobulin. DESCRIPTION: Synagis® (palivizumab) is a humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis® is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2). The human light chain sequence was derived from the constant domain of Ck and the variable framework regions of the VL gene K104 with Jk-4 (3). The murine sequences were derived from a murine monoclonal antibody, Mab 1129 (4), in a process that involved the grafting of the murine complementarity determining regions into the human antibody frameworks. Synagis® is composed of two heavy chains and two light chains and has a molecular weight of approximately 148,000 Daltons. n (%) n (%) Upper respiratory infection 830 (50.6) 544 (47.4) Otitis media 597 (36.4) 397 (34.6) Fever 446 (27.1) 289 (25.2) Rhinitis 439 (26.8) 282 (24.6) Hernia 68 (4.1) 30 (2.6) Hope this helps. http://www.vaccinetruth.org/page_15.htm RSV Virus I am adding this information on the new RSV treatment since lately I have seen so many babies receiving this protocol. First I will give you this question and answer that I found on an information website followed by the package insert. When you read the insert, keep in mind that " murine " means mouse. Basically they developed a murine or mouse antibody, overlaid it onto a human frame, and developed what they call a humanized chimeric monoclonal antibody (antibody produced artificially by a genetic engineering technique), which is 95% human and about 4 to 5% murine. This vaccine is given to premature babies once a month for six months and is extremely expensive. Read this article to see why using mouse molecules or other animal material is dangerous. Q: What is Respiratory Syncytial Virus (RSV) and how does it affect babies? Respiratory Syncytial Virus is the most common respiratory virus in infants and young children. It infects virtually all infants by the age of two years. In most infants, the virus causes symptoms resembling those of the common cold. In infants born prematurely and/or with chronic lung disease, RSV can cause a severe or even life-threatening disease. Each year, RSV disease results in over 125,000 hospitalizations, and about 2% of these infants die. Q: How is RSV transmitted? RSV is highly contagious. Each year, up to 50% of infants are infected. Transmission occurs by touching an infected person, and then rubbing your own eyes, nose, or mouth. The infection can also be spread through the air, by coughing and sneezing. RSV can survive for 4-7 hours on surfaces such as cribs and countertops. Transmission may be prevented by standard infection control practices, such as hand washing. Q: How often do ou.comreaks occur? RSV outbreaks occur each year on a fairly predictable schedule that varies from one region to another. In the United States, the “RSV season” usually begins in the Fall, and lasts through Spring. Q: How is RSV infection treated? Treatment of severe RSV infection is mostly supportive. It is important to help ensure that the infant is able to breathe, drink, eat and sleep comfortably. Your child's doctor may use a blood test to help determine the severity of the infection and the need for hospitalization. If your infant gets a severe case of RSV disease, the antiviral medication virazole (brand name Ribavirin®, a registered trademark of ICN) may be useful. Your child's doctor is the best source of information about the treatment of serious RSV disease. Q: Is there an RSV vaccine available? At this date, there is no RSV vaccine available. However, there is an effective prevention product available. During the RSV season (Fall through Spring), simple monthly injections of Synagis® (palivizumab) provide protection against serious lower respiratory tract infections caused by RSV in infants and children at high risk for RSV disease. Your child's doctor can provide complete information about RSV prevention and Synagis®. Ask your pediatrician for more information about RSV disease and Synagis® (palivizumab). Now for the package insert: SYNAGIS® (PALIVIZUMAB) for Intramuscular Administration DESCRIPTION: Synagis® (palivizumab) is a humanized monoclonal antibody (IgG1) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Palivizumab is a composite of human (95%) and murine (5%) (mouse) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2). The human light chain sequence was derived from the constant domain of Cand the variable framework regions of the VL gene K104 with J-4 (3). The murine sequences were derived from a murine monoclonal antibody, Mab 1129 (4), in a process which involved the grafting of the murine complementarity determining regions into the human antibody frameworks. Synagis® (palivizumab) is composed of two heavy chains and two light chains and has a molecular weight of approximately 148,000 Daltons. Synagis® (palivizumab) is supplied as a sterile lyophilized product for reconstitution with sterile water for injection. Reconstituted Synagis® (palivizumab) is to be administered by intramuscular injection only. Upon reconstitution, Synagis® (palivizumab) contains the following excipients: 47 mM histidine, 3.0 mM glycine and 5.6% mannitol and the active ingredient, palivizumab, at a concentration of 100 milligrams per mL solution. The reconstituted solution should appear clear or slightly opalescent. CLINICAL PHARMACOLOGY: Mechanism of Action: Synagis® (palivizumab) exhibits neutralizing and fusion-inhibitory activity against RSV. These activities inhibit RSV replication in laboratory experiments. Although resistant RSV strains may be isolated in laboratory studies, a panel of 57 clinical RSV isolates were all neutralized by Synagis® (palivizumab) (5). Synagis® (palivizumab) serum concentrations of 40 µg/mL have been shown to reduce pulmonary RSV replication in the cotton rat model of RSV infection by 100-fold (5). The in vivo neutralizing activity of the active ingredient in Synagis® (palivizumab) was assessed in a randomized, placebo controlled study of 35 pediatric patients tracheally intubated because of RSV disease. In these patients, palivizumab significantly reduced the quantity of RSV in the lower respiratory tract compared to control patients (6). Pharmacokinetics: In studies in adult volunteers Synagis® (palivizumab) had a pharmacokinetic profile similar to a human IgG1 antibody in regard to the volume of distribution and the half-life (mean 18 days). In pediatric patients less than 24 months of age, the mean half-life of Synagis® (palivizumab) was 20 days and monthly intramuscular doses of 15 mg/kg achieved mean ±SD 30 day trough serum drug concentrations of 37 ±21 µg/mL after the first injection, 57 ±41 µg/mL after the second injection, 68 ±51 µg/mL after the third injection and 72 ±50 µg/mL after the fourth injection (7). In pediatric patients given Synagis® (palivizumab) for a second season, the mean ±SD serum concentrations following the first and fourth injections were 61 ±17 µg/mL and 86 ±31µg/mL, respectively. CLINICAL STUDIES: The safety and efficacy of Synagis® (palivizumab) were assessed in a randomized, double-blind, placebo-controlled trial (IMpact-RSV Trial) of RSV disease prophylaxis among high-risk pediatric patients (7). This trial, conducted at 139 centers in the United States, Canada and the United Kingdom, studied patients 24 months of age with bronchopulmonary dysplasia (BPD) and patients with premature birth ( 35 weeks gestation) who were 6 months of age at study entry. Patients with uncorrected congenital heart disease were excluded from enrollment. In this trial, 500 patients were randomized to receive five monthly placebo injections and 1,002 patients were randomized to receive five monthly injections of 15 mg/kg of Synagis® (palivizumab). Subjects were randomized into the study from November 15 to December 13, 1996, and were followed for safety and efficacy for 150 days. Ninety-nine percent of all subjects completed the study and 93% received all five injections. The primary endpoint was the incidence of RSV hospitalization. RSV hospitalizations occurred among 53 of 500 (10.6%) patients in the placebo group and 48 of 1,002 (4.8%) patients in the Synagis® (palivizumab) group, a 55% reduction (p<0.001). The reduction of RSV hospitalization was observed both in patients enrolled with a diagnosis of BPD (34/266 [12.8%] placebo vs. 39/496 [7.9%] Synagis®[palivizumab]) and patients enrolled with a diagnosis of prematurity without BPD (19/234 [8.1%] placebo vs. 9/506 [1.8%] Synagis® [palivizumab]). The reduction of RSV hospitalization was observed throughout the course of the RSV season. Among secondary endpoints, the incidence of ICU admission during hospitalization for RSV infection was lower among subjects receiving Synagis® (palivizumab) (1.3%) than among those receiving placebo (3.0%), but there was no difference in the mean duration of ICU care between the two groups for patients requiring ICU care. Overall, the data do not suggest that RSV illness was less severe among patients who received Synagis® (palivizumab) and who required hospitalization due to RSV infection than among placebo patients who required hospitalization due to RSV infection. Synagis® (palivizumab) did not alter the incidence and mean duration of hospitalization for non-RSV respiratory illness or the incidence of otitis media. INDICATIONS AND USAGE: Synagis® (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease. Safety and efficacy were established in infants with bronchopulmonary dysplasia (BPD) and infants with a history of prematurity ( 35 weeks gestational age). (See Clinical Studies section) CONTRAINDICATIONS: Synagis® (palivizumab) should not be used in pediatric patients with a history of a severe prior reaction to Synagis® (palivizumab) or other components of this product. WARNINGS: Very rare cases of anaphylaxis (<1 case per 100,000 patients) have been reported following re-exposure to Synagis® (palivizumab) [see Adverse Reactions, Post-Marketing Experience]. Rare severe acute hypersensitivity reactions have also been reported on initial exposure or re-exposure to palivizumab. If a severe hypersensitivity reaction occurs, therapy with palivizumab should be permanently discontinued. If milder hypersensitivity reactions occur, caution should be used on readministration of palivizumab. If anaphylaxis or severe allergic reactions occur, administer appropriate medications (e.g., epinephrine) and provide supportive care as required. PRECAUTIONS: General: Synagis® (palivizumab) is for intramuscular use only. As with any intramuscular injection, Synagis® (palivizumab) should be given with caution to patients with thrombocytopenia or any coagulation disorder. The safety and efficacy of Synagis® (palivizumab) have not been demonstrated for treatment of established RSV disease. The single-use vial of Synagis® (palivizumab) does not contain a preservative. Injections should be given within 6 hours after reconstitution. Drug Interactions: No formal drug-drug interaction studies were conducted. In the IMpact-RSV trial, the proportions of patients in the placebo and Synagis® (palivizumab) groups who received routine childhood vaccines, influenza vaccine, bronchodilators or corticosteroids were similar and no incremental increase in adverse reactions was observed among patients receiving these agents. Carcinogenesis, Mutagenesis, Impairment of Fertility: Carcinogenesis, mutagenesis and reproductive toxicity studies have not been performed. Pregnancy: Pregnancy Category C: Synagis® (palivizumab) is not indicated for adult usage and animal reproduction studies have not been conducted. It is also not known whether Synagis® (palivizumab) can cause fetal harm when administered to a pregnant woman or could affect reproductive capacity. ADVERSE REACTIONS: In the combined pediatric prophylaxis studies of pediatric patients with BPD or prematurity involving 520 subjects receiving placebo and 1,168 subjects receiving 5 monthly doses of Synagis® (palivizumab), the proportions of subjects in the placebo and Synagis® (palivizumab) groups who experienced any adverse event or any serious adverse event were similar. Most of the safety information was derived from the IMpact-RSV trial. In this study, Synagis® (palivizumab) was discontinued in five patients: two because of vomiting and diarrhea, one because of erythema and moderate induration at the site of the fourth injection, and two because of pre-existing medical conditions which required management (one with congenital anemia and one with pulmonary venous stenosis requiring cardiac surgery). Seizures were reported in 0.6% of the placebo group and 0.4% of the Synagis® (palivizumab) group. Deaths in study patients occurred in five of 500 placebo recipients and four of 1,002 Synagis® (palivizumab) recipients. Sudden infant death syndrome was responsible for two of these deaths in the placebo group and one death in the Synagis® (palivizumab) group. Adverse events which occurred in more than 1% of patients receiving Synagis® (palivizumab) in the IMpact-RSV study for which the incidence in the Synagis® (palivizumab) group was 1% greater than in the placebo group are shown in Table 1. Table 1. Adverse Events Occurring in IMpact-RSV Study at Greater Frequency in the Synagis® (palivizumab) Group % of patients with: Placebo Synagis® (palivizumab) n = 500 n = 1,002 upper respiratory infection 49.0% 52.6% otitis media 40.0% 41.9% rhinitis 23.4% 28.7% rash 22.4% 25.6% pain 6.8% 8.5% hernia 5.0% 6.3% SGOT increased 3.8% 4.9% pharyngitis 1.4% 2.6% Other adverse events reported in more than 1% of the Synagis® (palivizumab) group included: fever, cough, wheeze, bronchiolitis, pneumonia, bronchitis, asthma, croup, dyspnea, sinusitis, apnea, failure to thrive, nervousness, diarrhea, vomiting, and gastroenteritis, SGPT increase, liver function abnormality, study drug injections site reaction, conjunctivitis, viral infection, oral monilia, fungal dermatitis, eczema, seborrhea, anemia and flu syndrome. The incidence of these adverse events was similar between the Synagis® (palivizumab) and placebo groups. IMMUNOGENICITY: In the IMpact-RSV trial, the incidence of anti-palivizumab antibody following the fourth injection was 1.1% in the placebo group and 0.7% in the Synagis® (palivizumab) group. In pediatric patients receiving Synagis® (palivizumab) for a second season, one of the fifty-six patients had transient, low titer reactivity. This reactivity was not associated with adverse events or alteration in Synagis® (palivizumab) serum concentrations. These data reflect the percentage of patients whose test results were considered positive for antibodies to Synagis® (palivizumab) in an ELISA assay, and are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors including sample handling, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to Synagis® (palivizumab) with the incidence of antibodies to other products may be misleading. POST-MARKETING EXPERIENCE: The following adverse reactions have been identified and reported during post-approval use of Synagis® (palivizumab). Because the reports of these reactions are voluntary and the population is of uncertain size, it is not always possible to reliably estimate the frequency of the reaction or establish a causal relationship to drug exposure. Based on experience in over 400,000 patients who have received Synagis® (palivizumab) (>2 million doses), rare severe acute hypersensitivity reactions have been reported on initial or subsequent exposure. Very rare cases of anaphylaxis (<1 case per 100,000 patients) have also been reported following re-exposure. None of the reported hypersensitivity reactions were fatal. Hypersensitivity reactions may include dyspnea, cyanosis, respiratory failure, urticaria, pruritis, angioedema, hypotonia and unresponsiveness. The relationship between these reactions and the development of antibodies to Synagis® (palivizumab) is unknown. Limited information from post- marketing reports suggests that, within a single RSV season, adverse events after a sixth or greater dose of Synagis® (palivizumab) are similar in character and frequency to those after the initial five doses. OVERDOSAGE: No data from clinical studies are available on overdosage. No toxicity was observed in rabbits administered a single intramuscular or subcutaneous injection of Synagis® (palivizumab) at a dose of 50 mg/kg. DOSAGE AND ADMINISTRATION: The recommended dose of Synagis® (palivizumab) is 15 mg/kg of body weight. Patients, including those who develop an RSV infection, should receive monthly doses throughout the RSV season. The first dose should be administered prior to commencement of the RSV season. In the northern hemisphere, the RSV season typically commences in November and lasts through April, but it may begin earlier or persist later in certain communities. Synagis® (palivizumab) should be administered in a dose of 15 mg/kg intramuscularly using aseptic technique, preferably in the anterolateral aspect of the thigh. The gluteal muscle should not be used routinely as an injection site because of the risk of damage to the sciatic nerve. The dose per month = [patient weight (kg) x 15 mg/kg ÷100 mg/mL of Synagis®(palivizumab)]. Injection volumes over 1 mL should be given as a divided dose. Preparation for Administration: •· To reconstitute, remove the tab portion of the vial cap and clean the rubber stopper with 70% ethanol or equivalent. •· Both the 50 mg and 100 mg vials contain an overfill to allow the withdrawal of 50 milligrams or 100 milligrams respectively when reconstituted following the directions described below. • Slowly add 0.6 mL of sterile water for injection to the 50 mg vial or add 1.0 mL of sterile water for injection to the 100 mg vial. The vial should be gently swirled for 30 seconds to avoid foaming. DO NOT SHAKE VIAL. • Reconstituted Synagis® (palivizumab) should stand at room temperature for a minimum of 20 minutes until the solution clarifies. •· Reconstituted Synagis® (palivizumab) does not contain a preservative and should be administered within 6 hours of reconstitution. To prevent the transmission of hepatitis viruses or other infectious agents from one person to another, sterile disposable syringes and needles should be used. Do not reuse syringes and needles. HOW SUPPLIED: Synagis® (palivizumab) is supplied in single use vials as lyophilized powder to deliver either 50 milligrams or 100 milligrams when reconstituted with sterile water for injection. 50 mg vial NDC 60574 -4112-1 Upon reconstitution the 50 mg vial contains 50 milligrams Synagis® (palivizumab) in 0.5 mL. 100 mg vial NDC 60574 -4111-1 Upon reconstitution the 100 mg vial contains 100 milligrams Synagis® (palivizumab) in 1.0 mL. Upon receipt and until reconstitution for use, Synagis® (palivizumab) should be stored between 2 and 8ºC (35.6º and 46.4ºF) in its original container. Do not freeze. Do not use beyond the expiration date. REFERENCES n = 500 n = 1,002 upper respiratory infection 49.0% 52.6% otitis media 40.0% 41.9% rhinitis 23.4% 28.7% rash 22.4% 25.6% pain 6.8% 8.5% hernia 5.0% 6.3% SGOT increased 3.8% 4.9% pharyngitis 1.4% 2.6% I found this article written before the vaccine was released to the general public. Some very interesting things are discovered I have highlighted them in bold. Dr. Jim Crowe assistant professor of Pediatrics and Microbiology at Vanderbilt conducted the trails of the RSV vaccine. This is excerpts from the article on him. It’s known that the immune systems of very young children don’t respond vigorously to vaccination. The B- and T-lymphocytes in the bloodstream that typically fight any type of foreign invading organism - which vaccines mimic - aren’t very effective in the first few months of a baby’s life. It’s not entirely clear, Crowe said, why infants differ from older children and adults in this regard. His lab is looking at the molecular level in individual infants to determine what genes are being used at the time of immunization to make an immune response. “Over the last two years,” Crowe said, “we’ve been able to get the first glimpses of why children are different from adults.” As a study model, Crowe is evaluating the immune response of infants in vaccine trials against respiratory syncycial virus, or RSV, at the Vanderbilt Vaccine Clinic. This particularly infectious virus affects most of us in our lifetimes, and can require hospitalization for some children. Being involved in the RSV vaccine trials has allowed Crowe and his co-workers to probe these questions about newborn immunity. In the trials, babies are intentionally infected with weakened virus at 4 weeks of age. (What! why would parents allow this?) The researchers monitor the genetic changes underlying whether a baby responds well to the vaccine or not. The vaccine trials will accept any age enrollee - from a very young child to an adult - to help define the immune system transition, but ultimately researchers need to understand the 2-4 week old babies, since they are most vulnerable to infection. Without the vaccine trials, Crowe said, they couldn’t do the research. “A unique opportunity presents itself by being able to intentionally infect a child on a known day with a known amount of virus,” he said. “We can measure titer (infection levels) of the virus, and also shedding of the virus. We know the full RNA sequence of the virus, which helps us in our genetic studies. It’s an extremely controlled situation.” Future plans include studying how premature infants differ from full-term babies in their immune response. The more pieces to the puzzle of immune system development that researchers discover, the better able they will be to come up with effective and safe vaccines not only to RSV, but to a host of other pathogens as well. Also take a look at this excerpt from N.Z. s' article entitled: The polio vaccine a critical assessment of its arcane history, efficacy and long term health related consequences found here http://www.thinktwice.com/Polio.pdf. Thousands of viruses and other potentially infectious micro-organisms thrive in monkeys and cows, the preferred animals for making polio vaccines [83:159]. SV-40, SIV, and BSE associated transmissible agents are just three of the disease-causing agents researchers have isolated. For example, scientists have known since 1955 that monkeys host the “B” virus, foamy agent virus, haemadsorption viruses, the LCM virus, arboviruses, and more [157]. Bovine immunodeficiency virus (BIV), similar in genetic structure to HIV, was recently found in some cows [103:100]. In 1956, respiratory syncytial virus (RSV) was discovered in chimpanzees [158]. According to Dr. Viera Scheibner, who studied more than 30,000 pages of medical papers dealing with vacci-nation, RSV viruses “formed prominent contaminants in polio vaccines, and were soon detected in children [159].” They caused serious cold-like symptoms in small infants and babies who received the polio vaccine [159]. In 1961, the Journal of the American Medical Association published two studies confirming a causal relationship between RSV and “relatively severe lower respiratory tract illness [160].” The virus was found in 57 percent of infants with bronchiolitis or pneumonia, and in 12 percent of babies with a milder febrile respiratory disease [161]. Infected babies remained ill for three to five months [161]. RSV was also found to be contagious, and soon spread to adults where it has been linked to the common cold [162]. Today, RSV infects virtually all infants by the age of two years, and is the most common cause of bronchiolitis and pneumonia among infants and children under one year of age [163]. It also causes severe respiratory disease in the elderly [164]. RSV re-mains highly contagious and results in thousands of hospitalizations every year; many people die from it [165]. Ironically, scientists are developing a vaccine to combat RSV [166]Cthe infectious agent that very likely entered the human population by way of a vaccine [159]. Dr. , a professor of pathology at the University of Southern California, has been warning authorities since 1978 that other dangerous monkey viruses could be contaminating polio vaccines. In particular, sought to investigate simian cytomegalovirus (SCMV), a “stealth virus” capable of causing neuro-logical disorders in the human brain. The virus was found in monkeys used for making polio vaccines. The government rebuffed his efforts to study the risks [83:15961]. However, in 1995, published his findings implicating the African green monkey as the probable source of SCMV isolated from a patient with chronic fatigue syndrome [167]. In 1996, Dr. B. Urnovitz, a microbiologist, founder and chief science officer of Calypte Biomedical in Berkeley, Cali-fornia spoke at a national AIDS conference where he revealed that up to 26 monkey viruses may have been in the original Salk vaccines. These included the simian equivalents of human echo virus, coxsackie, herpes (HHV-6, HHV-7, and HHV-8), adenoviruses, Epstein-Barr, and cytomegalovirus [168-170]. Urnovitz believes that contaminated Salk vaccines given to U.S. children between 1955 and 1961 may have set this generation up for immune system damage and neurological disorders. He sees correlations between early polio vaccine campaigns and the sudden emergence of human T-cell leukemia, epidemic Kaposi’s sarcoma, Burkitt’s lym-phoma, herpes, Epstein-Barr and chronic fatigue syndrome[168:1]. Urnovitz also discussed “jumping genes”—normal genes that may recombine with viral fragments to form new hybrid viruses called chimeras. He believes that this is exactly what happened when monkey viruses and human genes were brought together during early polio vaccine campaigns. And because the chimera “has the envelope of a normal human gene,” typical cures won’t work. How do you develop a vaccine or other antidote against the body’s own DNA [168:1-4;171]?16. Mutated polio strains Several years ago, the World Health Organization launched the Global Polio Eradication Initiative, with 2000 as its target date for eliminating the disease. However, by 2000 it became clear that not only was polio still around, but new strains of the disease—derived from the vaccine itself—were emerging [172]. Researchers first noticed something unusual in 1983. Outbreaks of polio in doi: 10.1588/medver.2004.01.00027 Page 16 -------------------------------------------------------- Sheri Nakken, former R.N., MA, Hahnemannian Homeopath Vaccination Information & Choice Network, Nevada City CA & Wales UK Vaccines - http://www.nccn.net/~wwithin/vaccine.htm or http://www.wellwithin1.com/vaccine.htm Vaccine Dangers & Homeopathy Online/email courses start in December 2008 http://www.wellwithin1.com/vaccineclass.htm or http://www.wellwithin1.com/homeo.htm Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 29, 2009 Report Share Posted January 29, 2009 I have just recently heard of Synagis because my twin nephews are taking it. I asked my sister in law what it was and all she could tell me was it's not a vaccination and even people who doin't vaccinate their children get it. Thank you for all the information you provided about Synagis and RSV. I had no idea how RSV came to be. I was just wondering if there is any new information since these posts are from November. If anyone nows anything new about the injection please let me know. Becky > > Synagis is made by MEdimmune which makes flumist > which is a terrifying vaccine with live flu > viruses sprayed into noses in stores & pharmacies > and is contagious for a good length of > time...............Medimmune has its facilities > in UK at the Chiron plant that had the > contaminated flu vaccine that was blocked a few years ago........... > > Also some of us think that RSV may be something > that follows polio vaccine - I can't explain that at the moment > Or even all the other vaccines that are given at > 12 houurs, 2 months, 3 months, 4 months, 6 > months.............certainly lower immune system resistance. > > Also, never was known when I was working PEDS > (didn't discover it until late 70's or > something). I don't remember horror and lots of > children with problems from anything resembling what they describe. > > Breastfeeding is excellent protection against > most illness; not vaccinating is excellent > protection; and finding a good homeopath if > illness does come up. But in my experience (and > I am in contact with thousands and thousands of > non-vaccinators), non-vaccinated children are the > healthiest children there are as a whole. > > Synagis is called a monoclonal antibody > http://www.medimmune.com/products/synagis/index.asp > > It would be hard to tell in this age group what > was a reaction to this stuff because they get so > many vaccines in the same time period > > > It is genetically engineered. If I remember > right, it comes from human immunglobulin - pooled > blood from a variety of people (I wouldn't want > anyone's pooled blood - the risk for who knows > what in my opinion is greater than any RSV > illness) It doesn't say that exactly but that is > the only way to get antibodies - from pooled blood immunglobulin. > > DESCRIPTION: Synagis® (palivizumab) is a > humanized monoclonal antibody (IgG1k) produced by recombinant DNA > technology, directed to an epitope in the A > antigenic site of the F protein of respiratory > syncytial virus (RSV). Synagis® is a > composite of human (95%) and murine (5%) antibody > sequences. The human heavy chain sequence was derived from the > constant domains of human IgG1 and the variable > framework regions of the VH genes Cor (1) and Cess (2). The human light > chain sequence was derived from the constant > domain of Ck and the variable framework regions of the VL gene K104 with > Jk-4 (3). The murine sequences were derived from > a murine monoclonal antibody, Mab 1129 (4), in a process that involved > the grafting of the murine complementarity > determining regions into the human antibody frameworks. Synagis® is composed of > two heavy chains and two light chains and has a > molecular weight of approximately 148,000 Daltons. > n (%) n (%) > Upper respiratory infection 830 (50.6) 544 (47.4) > Otitis media 597 (36.4) 397 (34.6) > Fever 446 (27.1) 289 (25.2) > Rhinitis 439 (26.8) 282 (24.6) > Hernia 68 (4.1) 30 (2.6) > > Hope this helps. > > http://www.vaccinetruth.org/page_15.htm > > > > RSV Virus > > I am adding this information on the new RSV > treatment since lately I have seen so many babies > receiving this protocol. First I will give you > this question and answer that I found on an > information website followed by the package > insert. When you read the insert, keep in mind > that " murine " means mouse. Basically they > developed a murine or mouse antibody, overlaid it > onto a human frame, and developed what they call > a humanized chimeric monoclonal antibody > (antibody produced artificially by a genetic > engineering technique), which is 95% human and > about 4 to 5% murine. This vaccine is given to > premature babies once a month for six months and > is extremely expensive. Read this article to see > why using mouse molecules or other animal material is dangerous. > > Q: What is Respiratory Syncytial Virus (RSV) and how does it affect babies? > Respiratory Syncytial Virus is the most common > respiratory virus in infants and young children. > It infects virtually all infants by the age of > two years. In most infants, the virus causes > symptoms resembling those of the common cold. In > infants born prematurely and/or with chronic lung > disease, RSV can cause a severe or even > life-threatening disease. Each year, RSV disease > results in over 125,000 hospitalizations, and about 2% of these infants die. > > Q: How is RSV transmitted? > > RSV is highly contagious. Each year, up to 50% of > infants are infected. Transmission occurs by > touching an infected person, and then rubbing > your own eyes, nose, or mouth. The infection can > also be spread through the air, by coughing and > sneezing. RSV can survive for 4-7 hours on > surfaces such as cribs and countertops. > Transmission may be prevented by standard > infection control practices, such as hand washing. > > Q: How often do ou.comreaks occur? > > RSV outbreaks occur each year on a fairly > predictable schedule that varies from one region > to another. In the United States, the " RSV > season " usually begins in the Fall, and lasts through Spring. > > Q: How is RSV infection treated? > > Treatment of severe RSV infection is mostly > supportive. It is important to help ensure that > the infant is able to breathe, drink, eat and > sleep comfortably. Your child's doctor may use a > blood test to help determine the severity of the > infection and the need for hospitalization. If > your infant gets a severe case of RSV disease, > the antiviral medication virazole (brand name > Ribavirin®, a registered trademark of ICN) may be > useful. Your child's doctor is the best source of > information about the treatment of serious RSV disease. > > Q: Is there an RSV vaccine available? > > At this date, there is no RSV vaccine available. > However, there is an effective prevention product > available. During the RSV season (Fall through > Spring), simple monthly injections of Synagis® > (palivizumab) provide protection against serious > lower respiratory tract infections caused by RSV > in infants and children at high risk for RSV > disease. Your child's doctor can provide complete > information about RSV prevention and Synagis®. > > Ask your pediatrician for more information about > RSV disease and Synagis® (palivizumab). > > Now for the package insert: > > SYNAGIS® (PALIVIZUMAB) > > for Intramuscular Administration > > DESCRIPTION: Synagis® (palivizumab) is a > humanized monoclonal antibody (IgG1) produced by > recombinant DNA technology, directed to an > epitope in the A antigenic site of the F protein > of respiratory syncytial virus (RSV). Palivizumab > is a composite of human (95%) and murine (5%) > (mouse) antibody sequences. The human heavy chain > sequence was derived from the constant domains of > human IgG1 and the variable framework regions of > the VH genes Cor (1) and Cess (2). The human > light chain sequence was derived from the > constant domain of Cand the variable framework > regions of the VL gene K104 with J-4 (3). The > murine sequences were derived from a murine > monoclonal antibody, Mab 1129 (4), in a process > which involved the grafting of the murine > complementarity determining regions into the > human antibody frameworks. Synagis® (palivizumab) > is composed of two heavy chains and two light > chains and has a molecular weight of > approximately 148,000 Daltons. Synagis® > (palivizumab) is supplied as a sterile > lyophilized product for reconstitution with > sterile water for injection. Reconstituted > Synagis® (palivizumab) is to be administered by > intramuscular injection only. Upon > reconstitution, Synagis® (palivizumab) contains > the following excipients: 47 mM histidine, 3.0 mM > glycine and 5.6% mannitol and the active > ingredient, palivizumab, at a concentration of > 100 milligrams per mL solution. The reconstituted > solution should appear clear or slightly opalescent. > > CLINICAL PHARMACOLOGY: Mechanism of Action: > Synagis® (palivizumab) exhibits neutralizing and > fusion-inhibitory activity against RSV. These > activities inhibit RSV replication in laboratory > experiments. Although resistant RSV strains may > be isolated in laboratory studies, a panel of 57 > clinical RSV isolates were all neutralized by > Synagis® (palivizumab) (5). Synagis® > (palivizumab) serum concentrations of 40 µg/mL > have been shown to reduce pulmonary RSV > replication in the cotton rat model of RSV > infection by 100-fold (5). The in vivo > neutralizing activity of the active ingredient in > Synagis® (palivizumab) was assessed in a > randomized, placebo controlled study of 35 > pediatric patients tracheally intubated because > of RSV disease. In these patients, palivizumab > significantly reduced the quantity of RSV in the > lower respiratory tract compared to control patients (6). > > Pharmacokinetics: In studies in adult volunteers > Synagis® (palivizumab) had a pharmacokinetic > profile similar to a human IgG1 antibody in > regard to the volume of distribution and the > half-life (mean 18 days). In pediatric patients > less than 24 months of age, the mean half-life of > Synagis® (palivizumab) was 20 days and monthly > intramuscular doses of 15 mg/kg achieved mean ±SD > 30 day trough serum drug concentrations of 37 ±21 > µg/mL after the first injection, 57 ±41 µg/mL > after the second injection, 68 ±51 µg/mL after > the third injection and 72 ±50 µg/mL after the > fourth injection (7). In pediatric patients given > Synagis® (palivizumab) for a second season, the > mean ±SD serum concentrations following the first > and fourth injections were 61 ±17 µg/mL and 86 ±31µg/mL, respectively. > > CLINICAL STUDIES: The safety and efficacy of > Synagis® (palivizumab) were assessed in a > randomized, double-blind, placebo-controlled > trial (IMpact-RSV Trial) of RSV disease > prophylaxis among high-risk pediatric patients > (7). This trial, conducted at 139 centers in the > United States, Canada and the United Kingdom, > studied patients 24 months of age with > bronchopulmonary dysplasia (BPD) and patients > with premature birth ( 35 weeks gestation) who > were 6 months of age at study entry. Patients > with uncorrected congenital heart disease were > excluded from enrollment. In this trial, 500 > patients were randomized to receive five monthly > placebo injections and 1,002 patients were > randomized to receive five monthly injections of > 15 mg/kg of Synagis® (palivizumab). Subjects were > randomized into the study from November 15 to > December 13, 1996, and were followed for safety > and efficacy for 150 days. Ninety-nine percent of > all subjects completed the study and 93% received > all five injections. The primary endpoint was the > incidence of RSV hospitalization. RSV > hospitalizations occurred among 53 of 500 (10.6%) > patients in the placebo group and 48 of 1,002 > (4.8%) patients in the Synagis® (palivizumab) > group, a 55% reduction (p<0.001). The reduction > of RSV hospitalization was observed both in > patients enrolled with a diagnosis of BPD (34/266 > [12.8%] placebo vs. 39/496 [7.9%] > Synagis®[palivizumab]) and patients enrolled with > a diagnosis of prematurity without BPD (19/234 > [8.1%] placebo vs. 9/506 [1.8%] Synagis® > [palivizumab]). The reduction of RSV > hospitalization was observed throughout the > course of the RSV season. Among secondary > endpoints, the incidence of ICU admission during > hospitalization for RSV infection was lower among > subjects receiving Synagis® (palivizumab) (1.3%) > than among those receiving placebo (3.0%), but > there was no difference in the mean duration of > ICU care between the two groups for patients > requiring ICU care. Overall, the data do not > suggest that RSV illness was less severe among > patients who received Synagis® (palivizumab) and > who required hospitalization due to RSV infection > than among placebo patients who required > hospitalization due to RSV infection. Synagis® > (palivizumab) did not alter the incidence and > mean duration of hospitalization for non-RSV > respiratory illness or the incidence of otitis media. > > INDICATIONS AND USAGE: Synagis® (palivizumab) is > indicated for the prevention of serious lower > respiratory tract disease caused by respiratory > syncytial virus (RSV) in pediatric patients at > high risk of RSV disease. Safety and efficacy > were established in infants with bronchopulmonary > dysplasia (BPD) and infants with a history of > prematurity ( 35 weeks gestational age). (See Clinical Studies section) > > CONTRAINDICATIONS: Synagis® (palivizumab) should > not be used in pediatric patients with a history > of a severe prior reaction to Synagis® > (palivizumab) or other components of this product. > > WARNINGS: Very rare cases of anaphylaxis (<1 case > per 100,000 patients) have been reported > following re-exposure to Synagis® (palivizumab) > [see Adverse Reactions, Post-Marketing > Experience]. Rare severe acute hypersensitivity > reactions have also been reported on initial > exposure or re-exposure to palivizumab. If a > severe hypersensitivity reaction occurs, therapy > with palivizumab should be permanently > discontinued. If milder hypersensitivity > reactions occur, caution should be used on > readministration of palivizumab. If anaphylaxis > or severe allergic reactions occur, administer > appropriate medications (e.g., epinephrine) and > provide supportive care as required. > > PRECAUTIONS: General: Synagis® (palivizumab) is > for intramuscular use only. As with any > intramuscular injection, Synagis® (palivizumab) > should be given with caution to patients with > thrombocytopenia or any coagulation disorder. The > safety and efficacy of Synagis® (palivizumab) > have not been demonstrated for treatment of established RSV disease. > > The single-use vial of Synagis® (palivizumab) > does not contain a preservative. Injections > should be given within 6 hours after > reconstitution. Drug Interactions: No formal > drug-drug interaction studies were conducted. In > the IMpact-RSV trial, the proportions of patients > in the placebo and Synagis® (palivizumab) groups > who received routine childhood vaccines, > influenza vaccine, bronchodilators or > corticosteroids were similar and no incremental > increase in adverse reactions was observed among > patients receiving these agents. > > Carcinogenesis, Mutagenesis, Impairment of > Fertility: Carcinogenesis, mutagenesis and > reproductive toxicity studies have not been > performed. Pregnancy: Pregnancy Category C: > Synagis® (palivizumab) is not indicated for adult > usage and animal reproduction studies have not > been conducted. It is also not known whether > Synagis® (palivizumab) can cause fetal harm when > administered to a pregnant woman or could affect reproductive capacity. > > ADVERSE REACTIONS: In the combined pediatric > prophylaxis studies of pediatric patients with > BPD or prematurity involving 520 subjects > receiving placebo and 1,168 subjects receiving 5 > monthly doses of Synagis® (palivizumab), the > proportions of subjects in the placebo and > Synagis® (palivizumab) groups who experienced any > adverse event or any serious adverse event were > similar. Most of the safety information was > derived from the IMpact-RSV trial. In this study, > Synagis® (palivizumab) was discontinued in five > patients: two because of vomiting and diarrhea, > one because of erythema and moderate induration > at the site of the fourth injection, and two > because of pre-existing medical conditions which > required management (one with congenital anemia > and one with pulmonary venous stenosis requiring > cardiac surgery). Seizures were reported in 0.6% > of the placebo group and 0.4% of the Synagis® > (palivizumab) group. Deaths in study patients > occurred in five of 500 placebo recipients and > four of 1,002 Synagis® (palivizumab) recipients. > Sudden infant death syndrome was responsible for > two of these deaths in the placebo group and one > death in the Synagis® (palivizumab) group. > Adverse events which occurred in more than 1% of > patients receiving Synagis® (palivizumab) in the > IMpact-RSV study for which the incidence in the > Synagis® (palivizumab) group was 1% greater than > in the placebo group are shown in Table 1. > > Table 1. Adverse Events Occurring in IMpact-RSV > Study at Greater Frequency in the Synagis® > (palivizumab) Group % of patients with: Placebo Synagis® (palivizumab) > > n = 500 n = 1,002 > > upper respiratory infection 49.0% 52.6% > > otitis media 40.0% 41.9% > > rhinitis 23.4% 28.7% > > rash 22.4% 25.6% > > pain 6.8% 8.5% > > hernia 5.0% 6.3% > > SGOT increased 3.8% 4.9% > > pharyngitis 1.4% 2.6% > > Other adverse events reported in more than 1% of > the Synagis® (palivizumab) group included: fever, > cough, wheeze, bronchiolitis, pneumonia, > bronchitis, asthma, croup, dyspnea, sinusitis, > apnea, failure to thrive, nervousness, diarrhea, > vomiting, and gastroenteritis, SGPT increase, > liver function abnormality, study drug injections > site reaction, conjunctivitis, viral infection, > oral monilia, fungal dermatitis, eczema, > seborrhea, anemia and flu syndrome. The incidence > of these adverse events was similar between the > Synagis® (palivizumab) and placebo groups. > > IMMUNOGENICITY: In the IMpact-RSV trial, the > incidence of anti-palivizumab antibody following > the fourth injection was 1.1% in the placebo > group and 0.7% in the Synagis® (palivizumab) > group. In pediatric patients receiving Synagis® > (palivizumab) for a second season, one of the > fifty-six patients had transient, low titer > reactivity. This reactivity was not associated > with adverse events or alteration in Synagis® > (palivizumab) serum concentrations. These data > reflect the percentage of patients whose test > results were considered positive for antibodies > to Synagis® (palivizumab) in an ELISA assay, and > are highly dependent on the sensitivity and > specificity of the assay. Additionally, the > observed incidence of antibody positivity in an > assay may be influenced by several factors > including sample handling, concomitant > medications, and underlying disease. For these > reasons, comparison of the incidence of > antibodies to Synagis® (palivizumab) with the > incidence of antibodies to other products may be misleading. > > POST-MARKETING EXPERIENCE: The following adverse > reactions have been identified and reported > during post-approval use of Synagis® > (palivizumab). Because the reports of these > reactions are voluntary and the population is of > uncertain size, it is not always possible to > reliably estimate the frequency of the reaction > or establish a causal relationship to drug > exposure. Based on experience in over 400,000 > patients who have received Synagis® (palivizumab) > (>2 million doses), rare severe acute > hypersensitivity reactions have been reported on > initial or subsequent exposure. Very rare cases > of anaphylaxis (<1 case per 100,000 patients) > have also been reported following re-exposure. > None of the reported hypersensitivity reactions > were fatal. Hypersensitivity reactions may > include dyspnea, cyanosis, respiratory failure, > urticaria, pruritis, angioedema, hypotonia and > unresponsiveness. The relationship between these > reactions and the development of antibodies to > Synagis® (palivizumab) is unknown. Limited > information from post- marketing reports suggests > that, within a single RSV season, adverse events > after a sixth or greater dose of Synagis® > (palivizumab) are similar in character and > frequency to those after the initial five doses. > > OVERDOSAGE: No data from clinical studies are > available on overdosage. No toxicity was observed > in rabbits administered a single intramuscular or > subcutaneous injection of Synagis® (palivizumab) at a dose of 50 mg/kg. > > DOSAGE AND ADMINISTRATION: The recommended dose > of Synagis® (palivizumab) is 15 mg/kg of body > weight. Patients, including those who develop an > RSV infection, should receive monthly doses > throughout the RSV season. The first dose should > be administered prior to commencement of the RSV > season. In the northern hemisphere, the RSV > season typically commences in November and lasts > through April, but it may begin earlier or > persist later in certain communities. Synagis® > (palivizumab) should be administered in a dose of > 15 mg/kg intramuscularly using aseptic technique, > preferably in the anterolateral aspect of the > thigh. The gluteal muscle should not be used > routinely as an injection site because of the > risk of damage to the sciatic nerve. The dose per > month = [patient weight (kg) x 15 mg/kg ÷100 > mg/mL of Synagis®(palivizumab)]. Injection > volumes over 1 mL should be given as a divided dose. > > Preparation for Administration: > > •· To reconstitute, remove the tab portion of the > vial cap and clean the rubber stopper with 70% ethanol or equivalent. > > •· Both the 50 mg and 100 mg vials contain an > overfill to allow the withdrawal of 50 milligrams > or 100 milligrams respectively when reconstituted > following the directions described below. > > • Slowly add 0.6 mL of sterile water for > injection to the 50 mg vial or add 1.0 mL of > sterile water for injection to the 100 mg vial. > The vial should be gently swirled for 30 seconds > to avoid foaming. DO NOT SHAKE VIAL. > > • Reconstituted Synagis® (palivizumab) should > stand at room temperature for a minimum of 20 > minutes until the solution clarifies. > > •· Reconstituted Synagis® (palivizumab) does not > contain a preservative and should be administered > within 6 hours of reconstitution. > > To prevent the transmission of hepatitis viruses > or other infectious agents from one person to > another, sterile disposable syringes and needles > should be used. Do not reuse syringes and needles. > > HOW SUPPLIED: Synagis® (palivizumab) is supplied > in single use vials as lyophilized powder to > deliver either 50 milligrams or 100 milligrams > when reconstituted with sterile water for > injection. 50 mg vial NDC 60574 -4112-1 Upon > reconstitution the 50 mg vial contains 50 > milligrams Synagis® (palivizumab) in 0.5 mL. 100 > mg vial NDC 60574 -4111-1 Upon reconstitution the > 100 mg vial contains 100 milligrams Synagis® > (palivizumab) in 1.0 mL. Upon receipt and until > reconstitution for use, Synagis® (palivizumab) > should be stored between 2 and 8ºC (35.6º and > 46.4ºF) in its original container. Do not freeze. > Do not use beyond the expiration date. > > REFERENCES > > n = 500 n = 1,002 > upper respiratory infection 49.0% 52.6% otitis > media 40.0% 41.9% rhinitis 23.4% 28.7% rash 22.4% > 25.6% pain 6.8% 8.5% hernia 5.0% 6.3% SGOT > increased 3.8% 4.9% pharyngitis 1.4% 2.6% > > I found this article written before the vaccine > was released to the general public. Some very > interesting things are discovered I have highlighted them in bold. > > Dr. Jim Crowe assistant professor of Pediatrics > and Microbiology at Vanderbilt conducted the > trails of the RSV vaccine. This is excerpts from > the article on him. It's known that the immune > systems of very young children don't respond > vigorously to vaccination. The B- and > T-lymphocytes in the bloodstream that typically > fight any type of foreign invading organism - > which vaccines mimic - aren't very effective in > the first few months of a baby's life. It's not > entirely clear, Crowe said, why infants differ > from older children and adults in this regard. > His lab is looking at the molecular level in > individual infants to determine what genes are > being used at the time of immunization to make an immune response. > > " Over the last two years, " Crowe said, " we've > been able to get the first glimpses of why > children are different from adults. " As a study > model, Crowe is evaluating the immune response of > infants in vaccine trials against respiratory > syncycial virus, or RSV, at the Vanderbilt > Vaccine Clinic. This particularly infectious > virus affects most of us in our lifetimes, and > can require hospitalization for some children. > Being involved in the RSV vaccine trials has > allowed Crowe and his co-workers to probe these > questions about newborn immunity. In the trials, > babies are intentionally infected with weakened > virus at 4 weeks of age. (What! why would parents > allow this?) The researchers monitor the genetic > changes underlying whether a baby responds well to the vaccine or not. > > The vaccine trials will accept any age enrollee - > from a very young child to an adult - to help > define the immune system transition, but > ultimately researchers need to understand the 2-4 > week old babies, since they are most vulnerable to infection. > > Without the vaccine trials, Crowe said, they couldn't do the research. > > " A unique opportunity presents itself by being > able to intentionally infect a child on a known > day with a known amount of virus, " he said. " We > can measure titer (infection levels) of the > virus, and also shedding of the virus. We know > the full RNA sequence of the virus, which helps > us in our genetic studies. It's an extremely controlled situation. " > > Future plans include studying how premature > infants differ from full-term babies in their > immune response. The more pieces to the puzzle of > immune system development that researchers > discover, the better able they will be to come up > with effective and safe vaccines not only to RSV, > but to a host of other pathogens as well. > > Also take a look at this excerpt from N.Z. > s' article entitled: The polio vaccine a > critical assessment of its arcane history, > efficacy and long term health related > consequences found here http://www.thinktwice.com/Polio.pdf. > > Thousands of viruses and other potentially > infectious micro-organisms thrive in monkeys and > cows, the preferred animals for making polio > vaccines [83:159]. SV-40, SIV, and BSE associated > transmissible agents are just three of the > disease-causing agents researchers have isolated. > For example, scientists have known since 1955 > that monkeys host the " B " virus, foamy agent > virus, haemadsorption viruses, the LCM virus, > arboviruses, and more [157]. Bovine > immunodeficiency virus (BIV), similar in genetic > structure to HIV, was recently found in some cows > [103:100]. In 1956, respiratory syncytial virus > (RSV) was discovered in chimpanzees [158]. > According to Dr. Viera Scheibner, who studied > more than 30,000 pages of medical papers dealing > with vacci-nation, RSV viruses " formed prominent > contaminants in polio vaccines, and were soon > detected in children [159]. " They caused serious > cold-like symptoms in small infants and babies > who received the polio vaccine [159]. > > In 1961, the Journal of the American Medical > Association published two studies confirming a > causal relationship between RSV and " relatively > severe lower respiratory tract illness [160]. " > The virus was found in 57 percent of infants with > bronchiolitis or pneumonia, and in 12 percent of > babies with a milder febrile respiratory disease > [161]. Infected babies remained ill for three to > five months [161]. RSV was also found to be > contagious, and soon spread to adults where it > has been linked to the common cold [162]. Today, > RSV infects virtually all infants by the age of > two years, and is the most common cause of > bronchiolitis and pneumonia among infants and > children under one year of age [163]. It also > causes severe respiratory disease in the elderly > [164]. RSV re-mains highly contagious and results > in thousands of hospitalizations every year; many > people die from it [165]. Ironically, scientists > are developing a vaccine to combat RSV [166]Cthe > infectious agent that very likely entered the > human population by way of a vaccine [159]. > > Dr. , a professor of pathology at > the University of Southern California, has been > warning authorities since 1978 that other > dangerous monkey viruses could be contaminating > polio vaccines. In particular, sought to > investigate simian cytomegalovirus (SCMV), a > " stealth virus " capable of causing neuro-logical > disorders in the human brain. The virus was found > in monkeys used for making polio vaccines. The > government rebuffed his efforts to study the > risks [83:15961]. However, in 1995, > published his findings implicating the African > green monkey as the probable source of SCMV > isolated from a patient with chronic fatigue > syndrome [167]. In 1996, Dr. B. Urnovitz, > a microbiologist, founder and chief science > officer of Calypte Biomedical in Berkeley, > Cali-fornia spoke at a national AIDS conference > where he revealed that up to 26 monkey viruses > may have been in the original Salk vaccines. > These included the simian equivalents of human > echo virus, coxsackie, herpes (HHV-6, HHV-7, and > HHV-8), adenoviruses, Epstein-Barr, and > cytomegalovirus [168-170]. Urnovitz believes that > contaminated Salk vaccines given to U.S. children > between 1955 and 1961 may have set this > generation up for immune system damage and > neurological disorders. He sees correlations > between early polio vaccine campaigns and the > sudden emergence of human T-cell leukemia, > epidemic Kaposi's sarcoma, Burkitt's lym-phoma, > herpes, Epstein-Barr and chronic fatigue syndrome[168:1]. > > Urnovitz also discussed " jumping genes " —normal > genes that may recombine with viral fragments to > form new hybrid viruses called chimeras. He > believes that this is exactly what happened when > monkey viruses and human genes were brought > together during early polio vaccine campaigns. > And because the chimera " has the envelope of a > normal human gene, " typical cures won't work. How > do you develop a vaccine or other antidote > against the body's own DNA [168:1-4;171]?16. > Mutated polio strains Several years ago, the > World Health Organization launched the Global > Polio Eradication Initiative, with 2000 as its > target date for eliminating the disease. However, > by 2000 it became clear that not only was polio > still around, but new strains of the > disease—derived from the vaccine itself—were > emerging [172]. Researchers first noticed > something unusual in 1983. Outbreaks of polio in > doi: 10.1588/medver.2004.01.00027 > Page 16 > > -------------------------------------------------------- > Sheri Nakken, former R.N., MA, Hahnemannian Homeopath > Vaccination Information & Choice Network, Nevada City CA & Wales UK > Vaccines - > http://www.nccn.net/~wwithin/vaccine.htm or > http://www.wellwithin1.com/vaccine.htm > Vaccine Dangers & Homeopathy Online/email courses start in December 2008 > http://www.wellwithin1.com/vaccineclass.htm or > http://www.wellwithin1.com/homeo.htm > Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.